Research Agreement with University of North Carolina
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The SRA will run for one year and involves joint ownership of any intellectual property developed during the research. Arovella's CEO expressed enthusiasm about this partnership and the recruitment of a talented scientist to advance their CAR-iNKT cell programs targeting solid tumours.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Reinstatement to Official Quotation
- Prospectus
- Arovella $15m Placement to fund Phase 1
- Voluntary Suspension
- Trading Halt
Later from Arovella Therapeutics
- S&P DJI Announces March 2025 Quarterly Rebalance
- Appendix 4E and Annual Report
- S&P DJI Announces September 2025 Quarterly Rebalance
- Arovella receives R&D tax rebate of $3.21 million
- CLDN18.2 CAR-T cells eliminate pancreatic cancer cells
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics